Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that it will highlight its ADAR (adenosine deaminases acting on RNA)-mediated RNA editing technology (“ADAR editing”) and its neurology programs in Huntington’s disease (HD), amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) at upcoming conferences,
September 15, 2020
· 5 min read
